Zoetis Inc. (ZTS)
Automate Your Wheel Strategy on ZTS
With Tiblio's Option Bot, you can configure your own wheel strategy including ZTS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ZTS
- Rev/Share 20.7462
- Book/Share 10.3999
- PB 15.9867
- Debt/Equity 1.4501
- CurrentRatio 1.7362
- ROIC 0.2254
- MktCap 74020282080.0
- FreeCF/Share 5.0961
- PFCF 32.4508
- PE 29.5544
- Debt/Assets 0.4788
- DivYield 0.0112
- ROE 0.5132
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Dr. Mark Stetter Elected to Zoetis Board of Directors
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE: ZTS) today announced the election of Dr. Mark Stetter to its Board of Directors, effective as of the company's annual shareholder meeting on May 21, 2025. Dr. Stetter brings extensive experience in veterinary medicine and animal health, including as Dean of the University of California, Davis School of Veterinary Medicine, to the Zoetis Board. His career in animal health includes pets, livestock, exotic animals, research and wildlife. He wil.
Read More
Zoetis (ZTS) Upgraded to Buy: Here's Why
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Zoetis (ZTS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Wall Street Analysts Think Zoetis (ZTS) Could Surge 26.18%: Read This Before Placing a Bet
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 26.2% in Zoetis (ZTS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Trade Tracker: Brenda Vingiello sells Zoetis and buys Quanta Services
Published: May 09, 2025 by: CNBC Television
Sentiment: Neutral
Brenda Vingiello, Chief Investment Officer at Sand Hill Global Advisors, joins 'Halftime Report' to detail her latest trades.
Read More
Zoetis' Q1: Market Overreaction Or Justified Drop?
Published: May 09, 2025 by: Seeking Alpha
Sentiment: Positive
The market did not like Zoetis Inc. earnings despite strong growth and the evidence that Zoetis is becoming a better business. Buybacks continued throughout the quarter and Zoetis is a good example of how consistent buybacks can become significant over long periods. Despite competitive pressures, key franchises like Simparica and Apoquel continue to grow. This portrays one of the attractive characteristics of the animal health industry.
Read More
Zoetis: Solid Q1 Results And A Weaker Dollar Provide Support (Upgrade)
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Zoetis shares have underperformed, losing 8% over the past year, but recent solid earnings and guidance suggest shares are nearer to fair value, shifting my stance from "sell" to "hold.". The company reported $1.48 EPS, beating estimates, with 9% organic growth despite foreign exchange headwinds; US dollar weakness should boost future results. Zoetis maintains a strong balance sheet, with $1.7 billion cash and $6.6 billion debt, supporting shareholder returns through buybacks and dividends.
Read More
Zoetis Inc. (ZTS) Q1 2025 Earnings Call Transcript
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Zoetis Inc. (NYSE:ZTS ) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ET Company Participants Steve Frank - Vice President of Investor Relations Kristin Peck - Chief Executive Officer Wetteny Joseph - Chief Financial Officer Conference Call Participants Erin Wright - Morgan Stanley Michael Ryskin - Bank of America Jon Block - Stifel David Westenberg - Piper Sandler Brandon Vazquez - William Blair Chris Schott - JPMorgan Navann Ty - BNP Paribas Daniel Clark - Leerink Partners Operator Welcome to the First Quarter 2025 Financial Results Conference Call and Webcast for Zoetis. Hosting the call today is Steve …
Read More
Zoetis Q1 Earnings & Revenues Beat Estimates, '25 Outlook Raised
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
ZTS reports better-than-expected first-quarter results as earnings and revenues surpass estimates. Management raises 2025 guidance.
Read More
Compared to Estimates, Zoetis (ZTS) Q1 Earnings: A Look at Key Metrics
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Zoetis (ZTS) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Zoetis (ZTS) Surpasses Q1 Earnings and Revenue Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Zoetis (ZTS) came out with quarterly earnings of $1.48 per share, beating the Zacks Consensus Estimate of $1.40 per share. This compares to earnings of $1.38 per share a year ago.
Read More
Zoetis Announces First Quarter 2025 Results
Published: May 06, 2025 by: Business Wire
Sentiment: Neutral
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the first quarter of 2025 and updated its full year 2025 guidance. The company reported revenue of $2.2 billion for the first quarter of 2025, an increase of 1% compared with the first quarter of 2024. On an organic operational1 basis, revenue for the first quarter of 2025 increased 9% compared with the first quarter of 2024. Net income for the first quarter of 2025 was $631 million, or $1.41 per.
Read More
MKKGY vs. ZTS: Which Stock Is the Better Value Option?
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Merck KGaA (MKKGY) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Zoetis (ZTS) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Neutral
Get a deeper insight into the potential performance of Zoetis (ZTS) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Read More
4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off
Published: April 26, 2025 by: The Motley Fool
Sentiment: Positive
It's always a good time to buy solid dividend stocks, but considering the challenging economic environment, now might be a particularly opportune time. Dividend-paying companies tend to have strong underlying operations and are generally more resilient than their non-dividend-paying counterparts.
Read More
1 Superstar Dividend Growth Stock to Buy if the Market Crashes
Published: April 26, 2025 by: The Motley Fool
Sentiment: Neutral
The stock market has entered a new period of increased uncertainty and volatility following the Trump Administration's desire to reshape America's trade policies. While the market hasn't crashed outright, it has experienced multiple sessions of sharp losses, as well as dramatic rebounds.
Read More
Trade Tracker: Sarat Sethi buys Zoetis and sells Elanco
Published: April 23, 2025 by: CNBC Television
Sentiment: Neutral
Sarat Sethi, Managing Partner at DCLA, joins CNBC's "Halftime Report" to detail his latest trades.
Read More
This Magnificent Dividend Stock Has Increased Its Payouts by 500% in 10 Years
Published: April 03, 2025 by: The Motley Fool
Sentiment: Positive
There are many dividend stocks on equity markets, but not all are attractive to income investors. Those that go beyond paying a quarterly payout but also consistently raise their dividends -- all while having robust businesses that can support their dividend programs for a long time -- are the ones income-seekers want.
Read More
Zoetis Inc. (ZTS) CFO Wetteny Joseph Hosts Barclays 27th Annual Global Healthcare (Transcript)
Published: March 11, 2025 by: Seeking Alpha
Sentiment: Neutral
Zoetis Inc. (NYSE:ZTS ) Barclays 27th Annual Global Healthcare March 11, 2025 10:30 AM ET Company Participants Wetteny Joseph - Chief Financial Officer Conference Call Participants Balaji Prasad - Barclays Balaji Prasad Good morning, everyone. Thanks for joining us at the Barclays Healthcare Conference.
Read More
My Top 15 High-Growth Dividend Stocks For March 2025
Published: March 03, 2025 by: Seeking Alpha
Sentiment: Positive
The SPDR S&P 500 ETF Trust stumbled in February but managed to maintain a positive return in 2025. The Top 15 dividend growth stocks for March 2025 offer an average dividend yield of 1.13% and appear to be about 25% undervalued based on dividend yield theory. Since its inception in September 2020, the watch list has achieved a 10.63% compound annual growth rate.
Read More
Zoetis Inc. (ZTS) BofA Securities 2025 Animal Health Summit (Transcript)
Published: February 28, 2025 by: Seeking Alpha
Sentiment: Neutral
Zoetis Inc. (NYSE:ZTS ) BofA Securities 2025 Animal Health Summit February 27, 2025 1:20 PM ET Company Participants Wetteny Joseph - CFO Conference Call Participants Michael Ryskin - Bank of America Operator Ladies and gentlemen, the program is about to begin. At this time, it is my pleasure to turn the program over to your host, Michael Ryskin.
Read More
Zoetis CEO on bird flu vaccine
Published: February 18, 2025 by: Bloomberg Markets and Finance
Sentiment: Positive
Zoetis received a conditional license for its bird flu vaccine from the US Department of Agriculture to help fight the spread of the disease on poultry farms. Here's what CEO Kristin Peck had to say
Read More
Why Zoetis Stock Took Another Tumble Today
Published: February 14, 2025 by: The Motley Fool
Sentiment: Negative
One day after unveiling quarterly results that disappointed the market and engendered a stock sell-off, Zoetis (ZTS -4.49%) shares again tumbled. As of late-session trading on Friday, they were down by 4%, in no small part due to several analyst price target cuts.
Read More
US grants conditional clearance to Zoetis' bird flu vaccine for poultry
Published: February 14, 2025 by: Reuters
Sentiment: Positive
Zoetis said on Friday its bird flu vaccine has received the U.S. Department of Agriculture's conditional license for use in poultry.
Read More
Zoetis CEO says Avian Flu vaccine for poultry gets USDA approval
Published: February 13, 2025 by: CNBC Television
Sentiment: Positive
Zoetis CEO Kristin Peck joins 'Closing Bell Overtime' to talk its Avian Flu vaccine, the impact of tariffs, and more.
Read More
Zoetis: In-Line Q4 Earnings And Weak Guidance Present A Buying Opportunity
Published: February 13, 2025 by: Seeking Alpha
Sentiment: Positive
Zoetis' Q4 earnings met expectations, but the stock fell due to slowing growth and cautious 2025 guidance, presenting a buying opportunity around $163/share. Zoetis' unique advantages and pricing power in animal health, coupled with high R&D investment and a wide moat, make it a strong long-term play on emerging market growth. Despite regulatory risks and currency headwinds, Zoetis' dependable earnings and high operating margins justify a 12-month price target of $200/share.
Read More
Zoetis forecasts 2025 profit, revenue below estimates; shares fall
Published: February 13, 2025 by: Reuters
Sentiment: Negative
Animal healthcare company Zoetis forecast annual profit and revenue below Wall Street estimates on Thursday, partly due to a hit from a stronger dollar, sending its shares down 9% in premarket trading.
Read More
Zoetis Reports Fourth Quarter and Full Year 2024 Results
Published: February 13, 2025 by: Business Wire
Sentiment: Neutral
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE: ZTS) today reported its financial results for the fourth quarter and full year 2024 as well as provided full year guidance for 2025. The company reported revenue of $2.3 billion for the fourth quarter of 2024, an increase of 5% compared with the fourth quarter of 2023. On an operational1 basis, revenue for the fourth quarter of 2024 increased 6% compared with the fourth quarter of 2023. Net income for the fourth quarter of 2024 was $581 mill.
Read More
About Zoetis Inc. (ZTS)
- IPO Date 2013-02-01
- Website https://www.zoetis.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Ms. Kristin C. Peck
- Employees 13800